Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

The Immunohistochemical Diagnostic Panel For Epithelial Mesothelioma: A Reevaluation After Heat-induced Epitope Retrieval.

J. R. Riera, C. Astengo-Osuna, J. Longmate, H. Battifora
Published 1997 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The immunohistochemical diagnosis between epithelial mesothelioma and adenocarcinoma is currently based on the use of a panel of antibodies to adenocarcinoma-associated antigens and a few antibodies to mesothelial-associated antigens. Since the introduction of epitope retrieval methods, the sensitivity of many antibodies has been enhanced. Thus, a reevaluation of the mesothelioma/adenocarcinoma diagnostic panel becomes necessary. We studied 268 paraffin-embedded formalin-fixed tumor samples that included 57 epithelial mesotheliomas and 211 adenocarcinomas of various origins, comparing an extensive antibody panel with and without heat-induced epitope retrieval (HIER). Marked increase in the sensitivity of several antibodies, with no loss of specificity, was found when HIER was used. After statistical analysis, the antibodies to the epithelial glycoproteins carcinoembryonic antigen, BerEp4, and Bg8 emerged as the best discriminators between adenocarcinoma and epithelial mesothelioma within the entire panel. The mesothelium-associated antibodies, HBME-1, calretinin, and thrombomodulin were less sensitive and less specific than the former, although they were found to be useful on certain cases. Antibodies to cytokeratins and vimentin, although of minor diagnostic value in this context, may be helpful to evaluate the quality of antigen preservation. This study confirms the value of immunohistochemistry to accurately distinguish mesothelioma from adenocarcinoma when an antibody panel approach is used. The addition of heat-induced epitope retrieval methods increases the effectiveness of the procedure and is recommended for most of the antibody panel members.
This paper references
Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma.
C. L. Collins (1992)
10.1093/AJCP/81.4.442
Keratins of different molecular weight in exfoliated mesothelial and adenocarcinoma cells--an aid to cell identification.
A. Walts (1984)
10.1097/00000478-198505000-00006
Immunohistochemical staining for vimentin and keratin in malignant mesothelioma
A. Churg (1985)
The diagnostic value of thrombomodulin immunolocalization in serous effusions.
V. Ascoli (1995)
10.1097/00000478-198604000-00001
Leu-Ml Antigen in Human Neoplasms: An Immunohistologic Study of 400 Cases
K. Sheibani (1986)
Malignant mesotheliomas. Improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44-3A6 and 624A12.
I. Lee (1986)
10.1097/00000478-198904000-00003
The Immunohistochemical Diagnosis of Mesothelioma: Differentiation of Mesothelioma and Lung Adenocarcinoma
N. Ordóñez (1989)
10.1007/BF00710235
The use of vimentin antibodies in the diagnosis of malignant mesothelioma
B. Jasani (2004)
10.1097/00000478-198803000-00004
The Diagnostic Utility of the Keratin Profiles of Hepatocellular Carcinoma and Cholangiocarcinoma
D. Johnson (1988)
Immunocytochemical differential diagnosis of diffuse malignant pleural mesotheliomas--a clinicomorphological study of 158 cases.
A. Vortmeyer (1991)
10.1016/0092-8674(82)90324-5
The mesothelial keratins: A new family of cytoskeletal proteins identified in cultured mesothelial cells and nonkeratinizing epithelia
Ying-Jye Wu (1982)
10.1002/1097-0142(19850415)55:8<1679::AID-CNCR2820550812>3.0.CO;2-C
Distinction of mesothelioma from adenocarcinoma. An immunohistochemical approach
H. Battifora (1985)
10.1016/0006-291X(90)90793-M
Protein kinase C subspecies in estrogen receptor-positive and -negative human breast cancer cell lines.
E. Bignon (1990)
10.1097/00000478-199108000-00008
Ber‐EP4 Antibody as a Discriminant in the Differential Diagnosis of Malignant Mesothelioma Versus Adenocarcinoma
K. Sheibani (1991)
10.1093/AJCP/88.3.286
The distribution of vimentin and keratin in epithelial and nonepithelial neoplasms. A comprehensive immunohistochemical study on formalin- and alcohol-fixed tumors.
N. Azumi (1987)
10.1097/00000478-198706000-00005
Immunohistochemical Evaluation of Pleural Mesothelioma and Pulmonary Adenocarcinoma: A Bi-institutional Study of 47 Cases
C. Otis (1987)
10.1016/0046-8177(89)90202-5
Immunohistochemical distinction of malignant mesothelioma from pulmonary adenocarcinoma with anti-surfactant apoprotein, anti-Lewisa, and anti-Tn antibodies.
M. Noguchi (1989)
10.1093/AJCP/86.4.556
Staining properties of melanin and lipofuscin pigments.
M. Senba (1986)
Mesothelioma: profile of keratin proteins and carcinoembryonic antigen: an immunoperoxidase study of 20 cases and comparison with pulmonary adenocarcinomas.
J. Corson (1982)
10.1097/00000478-199206000-00007
Immunoreactivity for BER‐EP4 in Adenocarcinomas, Adenomatoid Tumors, and Malignant Mesotheliomas
M. Gaffey (1992)
10.1111/j.1365-2559.1995.tb01527.x
A comparative immunohistochemical study of malignant mesothelioma and renal cell carcinoma: the diagnostic utility of Leu‐M1, Ber EP4, Tamm‐Horsfall protein and thrombomodulin
R. Attanoos (1995)
10.1007/BF02889950
Simultaneous immunoenzyme staining of vimentin and cytokeratins with monoclonal antibodies as an aid in the differential diagnosis of malignant mesothelioma from pulmonary adenocarcinoma
H. Mullink (1986)
10.1016/0046-8177(93)90080-Z
Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma.
R. Brown (1993)
10.1016/0046-8177(92)90231-Q
Immunopathologic and molecular studies as an aid to the diagnosis of malignant mesothelioma.
K. Sheibani (1992)
10.1097/00000478-199609000-00001
Calretinin: a novel immunocytochemical marker for mesothelioma.
C. Doglioni (1996)
10.1002/IJC.2910410210
Monoclonal antibodies against mesothelial membrane antigen discriminate between malignant mesothelioma and lung adenocarcinoma
Rolf A. Stahel (1988)
10.1097/00000478-199612000-00001
Malignant vascular tumors of the serous membranes mimicking mesothelioma. A report of 14 cases.
B. T. Lin (1996)
The intermediate filament cytoskeleton of malignant mesotheliomas and its diagnostic significance.
G. Blobel (1985)
Expression of a 130-kDa mesothelial and ciliated cell Ag (MCp130) in normal and developing human and rat lung and its role as a diagnostic marker for mesotheliomas and tumors of the female reproductive system.
G. Singh (1995)
Immunocytochemistry in the differential diagnosis of effusions: use of logistic regression to select a panel of antibodies to distinguish adenocarcinomas from mesothelial proliferations.
D. Frisman (1993)
10.1002/PATH.1711650209
Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma
M. Delahaye (1991)
Immunohistochemical properties of malignant mesothelioma cells in histologic and cytologic specimens.
T. Motoyama (1995)
10.1016/0046-8177(93)90079-V
The search for the optimal immunohistochemical panel for the diagnosis of malignant mesothelioma.
L. Weiss (1993)
10.1002/1097-0142(19940115)73:2<464::AID-CNCR2820730235>3.0.CO;2-#
Carcinoembryonic antigen‐like reactivity in malignant mesothelioma. A comparison between different commercially available antibodies
A. Dejmek (1994)
10.1136/jcp.43.3.213
Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelial.
U. Latza (1990)
10.1007/BF02890064
Expression of keratin 5 as a distinctive feature of epithelial and biphasic mesotheliomas
R. Moll (1989)
10.1093/AJCP/88.5.610
Immunohistochemical staining in malignant mesotheliomas.
J. G. Strickler (1987)
10.1097/00000478-199203000-00006
Monoclonal Antibody K1 Reacts With Epithelial Mesothelioma but not With Lung Adenocarcinoma
K. Chang (1992)
ME1. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies.
C. O'hara (1990)
10.1136/jcp.37.11.1215
Use of antibodies to carcinoembryonic antigen and human milk fat globule to distinguish carcinoma, mesothelioma, and reactive mesothelium.
R. J. Marshall (1984)
10.1016/0046-8177(90)90036-5
Malignant epithelioid pleural mesothelioma versus peripheral pulmonary adenocarcinoma: a histochemical, ultrastructural, and immunohistologic study of 103 cases.
M. Wick (1990)
10.1016/s0169-5002(87)80458-0
Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.
K. Sheibani (1986)
10.1111/j.1365-2559.1996.tb01393.x
Mesothelioma‐binding antibodies: thrombomodulin, OV 632 and HBME‐1 and their use in the diagnosis of malignant mesothelioma
R. Attanoos (1996)
10.1111/j.1699-0463.1994.tb04873.x
Immunohistochemical reactivity in mesothelioma and adenocarcinoma: A stepwise logistic regression analysis
A. Dejmek (1994)
Blood group antigens, Lewisx and Lewisy in the diagnostic discrimination of malignant mesothelioma versus adenocarcinoma.
D. Jordon (1989)



This paper is referenced by
10.1038/modpathol.3800067
Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers
J. Trupiano (2004)
10.1038/modpathol.3800471
The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study
N. Ordóñez (2006)
10.5858/arpa.2018-0457-OA
Differential Diagnosis of Epithelioid Malignant Mesothelioma With Lung and Breast Pleural Metastasis: A Systematic Review Compared With a Standardized Panel of Antibodies-A New Proposal That May Influence Pathologic Practice.
N. Le Stang (2019)
10.1016/S0761-8425(06)71783-1
2.2. Quels critères pour le diagnostic anatomopathologique du mésothéliome pleural malin
F. Galateau-Sallé (2006)
10.1309/PJ7H-A52V-M3XB-V94Y
Use of a panel of markers in the differential diagnosis of adenocarcinoma and reactive mesothelial cells in fluid cytology.
E. C. Ko (2001)
10.1097/00000478-200105000-00007
Calretinin and Other Mesothelioma Markers in Synovial Sarcoma: Analysis of Antigenic Similarities and Differences With Malignant Mesothelioma
M. Miettinen (2001)
10.1038/modpathol.3800534
Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity
H. Yaziji (2006)
10.1182/blood-2016-01-696104
Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice.
B. Cooley (2016)
10.1097/00132583-200107000-00004
Effusion Cytology of Metastatic Malignancy of Unknown Primary
J. Silverman (2001)
10.1002/(SICI)1097-0142(20000225)90:1<55::AID-CNCR8>3.0.CO;2-P
Cytologic differential diagnosis among reactive mesothelial cells, malignant mesothelioma, and adenocarcinoma
H. Kitazume (2000)
10.1016/j.lungcan.2009.01.011
Accuracy of pathological diagnosis of mesothelioma cases in Japan: clinicopathological analysis of 382 cases.
Y. Takeshima (2009)
10.1016/J.ANNDIAGPATH.2006.08.009
Pseudomesotheliomatous carcinoma of the lung with a distinct morphology, immunohistochemistry, and comparative genomic hybridization profile.
J. Pardo (2007)
10.1136/JCP.54.10.766
Malignant mesothelioma: a comparison of biopsy and postmortem material by light microscopy and immunohistochemistry.
F. Roberts (2001)
10.1007/s00418-004-0701-1
Establishment of permanent cell lines purified from human mesothelioma: morphological aspects, new marker expression and karyotypic analysis
M. Philippeaux (2004)
10.1046/j.1365-2559.2001.01092.x
Immunohistochemistry and the diagnosis of malignant mesothelioma
J. King (2001)
10.1309/QHCA-8594-TA7P-0DVQ
An optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma.
U. Brockstedt (2000)
10.1002/(SICI)1097-0339(200002)22:2<113::AID-DC12>3.0.CO;2-6
Mesothelial hyperplasia with reactive atypia: Diagnostic pitfalls and role of immunohistochemical studies—a case report
A. Lee (2000)
10.1017/cbo9781316167366
Modern Immunohistochemistry by Peiguo Chu
P. Chu (2000)
10.1097/PAS.0b013e31825d5371
Utility of a CEA, CD15, Calretinin, and CK5/6 Panel for Distinguishing Between Mesotheliomas and Pulmonary Adenocarcinomas in Clinical Practice
T. Mohammad (2012)
10.1002/1097-0339(200102)24:2<149::AID-DC1031>3.0.CO;2-F
Calretinin immunostaining in benign and malignant pleural effusions
A. Simsir (2001)
10.1053/HUPA.2002.128248
Immunohistochemical diagnosis of epithelioid mesotheliomas: a critical review of old markers, new markers.
N. Ordóñez (2002)
10.1309/AJCP0B3YJBXWXJII
Value of claudin-4 immunostaining in the diagnosis of mesothelioma.
N. Ordóñez (2013)
10.1093/PPR/114.1.S68
Cytopathology of pleural mesotheliomas.
G. Nguyen (2000)
10.1038/modpathol.3800736
D2-40 and calretinin—a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation
Marc Hinterberger (2007)
10.1016/B978-0-443-06652-8.50016-8
Chapter 10 – Immunohistology of the Mediastinum
M. Wick (2006)
10.1111/j.1440-1843.2005.00765.x
Clinicopathological analysis of lung cancer resembling malignant pleural mesothelioma
Y. Kobashi (2005)
10.1002/cncr.9044
Immunocytochemistry in effusion cytology
P. Fetsch (2001)
10.1007/978-1-4939-1516-3_5
Immunohistochemistry in the Study of Cancer Biomarkers for Oncology Drug Development
F. Jiang (2016)
10.1159/000328503
Inflammatory pseudotumor of the kidney: report of a case with fine needle aspiration cytology.
T. Kobayashi (2000)
10.1002/DC.20203
Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids
E. Politi (2005)
10.1016/B978-1-4160-5766-6.00012-1
Chapter 8 – Immunohistology of Metastatic Carcinomas of Unknown Primary
R. Bhargava (2011)
10.1002/bjs.5377
Sex difference in diffuse malignant peritoneal mesothelioma
T. Yan (2006)
See more
Semantic Scholar Logo Some data provided by SemanticScholar